Next Editor in Chief Named for Premier Hepatology Journal

ALEXANDRIA, VA – Today the American Association for the Study of Liver Diseases (AASLD) announced the appointment of the next editor in chief for their flagship journal, HEPATOLOGY. Dr. Gregory Gores, FAASLD, will take over from Dr. David Cohen, FAASLD, in January 2022, and his editorial team will begin reviewing manuscripts in July 2021.

“I am truly honored and very excited to become the next editor in chief of HEPATOLOGY,” said Dr. Gores. “I am humbled to take over from Dr. Cohen and will continue to uphold the standard of excellence for which this flagship publication is known. I look forward to assembling my editorial team and interacting with AASLD members to take HEPATOLOGY to the next level during my tenure and beyond.”

First published in January 1981, HEPATOLOGY is AASLD’s premier publication with a current impact factor of 14.679. The journal’s strong standing in the field is fueled by the roughly 2400 total manuscript submissions, and nearly 2000 original research manuscript submissions, it receives each year, leading to approximately 300,000 full article downloads each month.

“We are thrilled that Dr. Gores has accepted the role as the next editor in chief of our most prestigious journal,” said Dr. Jorge Bezerra, President of AASLD. “He is a highly respected and globally recognized leader in our field and we know he will carry on HEPATOLOGY’s legacy of excellence. The AASLD Governing Board is grateful to Dr. Cohen and his editorial team who have done an outstanding job leading the journal over the last five years.”

Gores is a hepatologist at the Mayo Clinic in Rochester, MN with contributions to research, clinical practice, and education. He is uniquely positioned to take over as editor in chief in part thanks to having twice served as an associate editor for the prestigious journal, as well as his standing as a past president for AASLD.

His research contributions include sustained federal funding over three decades, over 700 publications, an H-index of 136, and over 57,000 citations (Scopus data base). His clinical focus on hepatobiliary neoplasia has led to novel protocols regarding liver transplantation for cholangiocarcinoma. He has also mentored over 80 fellows while directing a liver transplant fellowship program.

His work has earned him many accolades, including AASLD’s Distinguished Service Award and awards from Mayo Alumni Association, the German Society of Gastroenterology the Canadian Liver Foundation and Canadian Association for the Study of Liver.

About the AASLD AASLD is the leading organization of clinicians and researchers committed to preventing and curing liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.

Press releases and additional information about AASLD are available online at www.aasld.org.